View Full Version : Oral Turinabol~4-chlorodehydromethyltestosterone

12-27-2010, 03:14 PM

Androgenic: N/A
Anabolic: >100
Standard: Methyltestosterone
Chemical Name: 4-chloro-17a-methyl-17b- hydroxyandrosta-1,4-dien-3-one
Estrogenic Activity: none
Progestational Activity: very low

Chlorodehydromethyltestosterone is a potent derivative of Dianabol. This oral steroid is structurally a cross between methandrostenolone and clostebol (4-chlorotestosterone), having the same base structure as Dianabol with the added 4-chloro alteration of clostebol. This alteration makes chlorodehydromethyltestosterone a milder cousin of Dianabol, the new steroid displaying no estrogenic and a much less androgenic activity in comparison to its more famous counterpart. The anabolic activity of tbol is somewhat lower than that of Dianabol as well, but it does maintain a much more favorable balance of anabolic to androgenic effect. This means that at any given level of muscle-building activity, chlorodehydromethyltestosterone will be less likely to
produce androgenic side effects.

Administration (Men):
A common clinical dose of tbol is estimated to be 5 mg per day; actual prescribing guidelines are unavailable. In the athletic arena, an effective oral daily dosage falls in the range of 15-40 mg, taken in cycles lasting no more than 6-8 weeks to minimize hepatotoxicity. This level is sufficient for measurable increases in lean muscle mass and strength. This agent is most often applied as a pre- contest or cutting steroid for bodybuilding purposes, and is not viewed as an ideal bulking agent due to its lack of estrogenicity. Athletes in sports where speed tends to be a primary focus also find strong favor in chlorodehydromethyltestosterone, obtaining a strong anabolic benefit without having to carry around any extra water or fat weight.

Administration (Women):
A common clinical dose of tbol is estimated to be 1- 2.5 mg per day; actual prescribing guidelines are unavailable. In the athletic arena, women would commonly take a single 5 mg tablet per day, taken in cycles lasting no more than 4-6 weeks to minimize hepatotoxicity. Virilizing effects are unlikely at this level of use. Much higher doses were often used with female athletes in the former GDR doping program, but often to detriment of strong virilizing side effects.

Side Effects:
The potential side effects of OT usually depend on the dosage level and are gender-specific. in women, depending on their predisposi-tion, the usual virilization symptoms occur and increase when dos-ages of more than 20 mg per day are taken over a prolonged time. In men the already discussed reduced testosterone production can rarely be avoided. Gynecomastia occurs rarely with OT Since the response of the water and electrolyte household is not overly dis-tinct athletes only rarely report water retention and high blood pressure. Acne, gastrointestinal pain, and uncontrolled aggressive behavior are also the exception rather than the rule with OT An increased libido is reported in most cases by both sexes. Since the substance chlordehydromethyltestosterone is I 7-alpha alkylated the manufacturer in its package insert recommends that the liver func-tion be checked regularly since it can be negatively affected by high dosages and the risk of possible liver damage cannot be excluded. Thus OT is also a steroid that can be taken without interruption for long intervals. Studies of male athletes who over a period of six weeks were given 10 mg OT/day did not show any indications of health-threatening effects.

Tbol is no longer available as a prescription drug product. Several export and underground manufacturers do sell this steroid, however.

Llewellyn’s W. (2009). Anabolics (9th ed), Oral Turinabol (p. 339-341): Jupiter, FL: Molecular Nutrition
Steroid.com ORAL-TURINABOL; 2009

12-27-2010, 03:30 PM
Intratesticular leiomyosarcoma in a young man after high dose doping with Oral-Turinabol: a case report.

Froehner M (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Froehner%20M%22%5BAuthor%5D), Fischer R (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Fischer%20R%22%5BAuthor%5D), Leike S (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Leike%20S%22%5BAuthor%5D), Hakenberg OW (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Hakenberg%20OW%22%5BAuthor%5D), Noack B (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Noack%20B%22%5BAuthor%5D), Wirth MP (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Wirth%20MP%22%5BAuthor%5D).
Department of Urology, Universitaetsklinikum "Carl Gustav Carus," Technical University of Dresden, Dresden, Germany.
Comment in:

Cancer. 2000 May 1;88(9):2195-7. (http://www.ncbi.nlm.nih.gov/pubmed/10813736)


BACKGROUND: Androgenic anabolic steroids have been suspected of activity as carcinogens in the development of carcinoma and angiosarcoma of the liver and adenocarcinoma of the prostate. Although the proliferation of smooth muscle cells is stimulated by sexual steroids, to the authors' knowledge a possible relation between androgenic anabolic steroids and the development of leiomyosarcoma has not previously been reported in humans.
METHODS: A 32-year-old man underwent right radical orchiectomy for a tumor of the upper pole of the right testicle. Routine histopathologic examination and immunohistochemical staining were performed.
RESULTS: The tumor was identified as an intratesticular leiomyosarcoma based on its typical growth pattern and the characteristic immunohistochemical staining profile. The patient reported a 5-year history of systematic use of high dose Oral-Turinabol (4-chloro-1-dehydro-17alpha-methylteststerone) that began at age 18 years and stopped approximately 9 years before presentation.
CONCLUSIONS: The rarity of intratesticular leiomyosarcoma, the experimental induction of similar tumors in animals by androgens and estrogens, and the unusually young age at presentation of the patient in the current study support the hypothesis that high dose doping with androgenic anabolic steroids could have played a cocarcinogenic role in the development of the tumor in this case.